The Delta Variant: Implications for Vaccines, Booster Shots and Economic Growth

Episode Summary

Executive Summary: The episode examines how the Delta variant changed the reopening outlook. Terrence Flynn explains that Delta is more transmissible but vaccines still strongly protect against severe disease, especially after two doses, while boosters may be needed for high-risk groups and potentially later more broadly. Dan Struven then shows Delta’s uneven economic effects: Europe is improving, the U.S. is slowing modestly, and parts of emerging Asia are facing sharper downside risks, with growth forecasts trimmed mainly because of renewed caution, slower services recovery, and supply bottlenecks.

Main Topics: Delta variant characteristics and why it matters (Priority: 5/5): Delta spreads faster, can infect people over shorter exposures, and can transmit from vaccinated individuals, making it more disruptive than earlier strains. Vaccine effectiveness against Delta (Priority: 5/5): Two-dose vaccination still provides strong protection, especially against severe disease and hospitalization, though protection against symptomatic infection is weaker than against prior variants and lower after one dose. Breakthrough infections and severity (Priority: 4/5): Breakthrough cases remain rare and are generally milder, with substantially lower symptoms and very few severe outcomes among the fully vaccinated. Booster shots and next-generation vaccines (Priority: 4/5): Booster need is tied to waning immunity and variant escape; high-risk groups are first in line, while companies are preparing both same-formulation boosters and variant-specific vaccines. Regional economic impact of Delta (Priority: 5/5): The economic effect differs by geography: the UK and parts of Europe are rebounding, the U.S. is slowing moderately, and Asia-Pacific faces more pressure from outbreaks and restrictions. Growth forecast revisions and broader risks (Priority: 4/5): Goldman Sachs lowered some growth forecasts, especially in the U.S. and Asia-Pacific, and sees the main risks as new variants and slower-than-expected recovery in supply chains and labor markets.

Key Arguments: Delta is more transmissible than earlier variants, which is why it became the dominant strain globally. Vaccines still work very well against Delta, particularly after two doses and especially against hospitalization and severe disease. Single-dose protection against Delta is materially weaker, so completing vaccination is critical. Breakthrough infections can occur but are usually less severe and less common than infections among the unvaccinated. Boosters may be needed because immunity can wane over time and future variants could evade existing protection. Manufacturers are preparing both third doses of existing vaccines and variant-specific boosters as contingency planning. Economic effects are uneven: Europe appears to be following the UK’s reopening rebound, while the U.S. is seeing a modest slowdown in consumer services and return-to-office activity. Vaccination rates strongly correlate with hospitalization rates across U.S. states, and national virus headlines affect consumer behavior even in high-vaccination areas. Asia-Pacific faces bigger downside risk because of lower natural immunity, later vaccine rollout, and tougher containment policies. The biggest macro downside risk is a new variant that is both more transmissible and more capable of escaping vaccine protection. A slower global supply-side recovery and labor market frictions could also weigh on growth beyond the direct health effects of Delta.

Data Points: Pfizer/BioNTech efficacy after 2 doses vs symptomatic Delta: 88% - UK real-world study cited by Terrence Flynn Pfizer/BioNTech efficacy after 2 doses vs Alpha: 93% - Comparison used to show only modest decline from earlier variant Pfizer/BioNTech efficacy after 1 dose vs Delta: About 30% - UK data on single-dose protection Pfizer/BioNTech efficacy after 2 doses vs symptomatic COVID in Israel: About 40% - Israeli data suggesting possible waning over time Vaccine efficacy vs severe disease/hospitalization: Around 90% - Data from Israel and Canada, even with Delta Breakthrough infection symptom reduction: 60% lower flu-like symptoms - Earlier-pandemic data comparing vaccinated breakthrough cases to unvaccinated infections Breakthrough illness duration: About 2 fewer days in bed - Earlier-pandemic data on vaccinated breakthrough cases Fully vaccinated U.S. population: More than 160 million - CDC data through end of July 2021 Severe breakthrough cases in U.S.: About 6,600 hospitalizations or deaths - CDC data among fully vaccinated people through end of July National U.S. hospitalizations: 55,000 people - Current U.S. hospital count cited by Dan Struven Florida hospitalization rate: 1 out of 2,000 people - Example of high hospitalization burden in a low-vaccination state Vermont hospitalization rate: 1 out of 100,000 people - Example of low hospitalization burden in a highly vaccinated state Alabama vaccination rate: Around 43% of the full population - Used to illustrate U.S. regional vaccination gaps Northeast adult vaccination rate: More than 90% - Vermont, Massachusetts and nearby areas cited as high-vaccination regions U.S. share feeling protected: 38% - Gallup poll after falling from 50% the prior month U.S. consumption growth forecast revision: Down by 2 percentage points annualized in the second half - Goldman Sachs downgrade due to Delta and slower reopening Global growth forecast gap vs consensus: Narrowed from about 1 percentage point to 0.3 percentage points - Comparison of Goldman Sachs outlook versus market consensus U.S. growth path: From around 7% growth this summer to 1.5%–2% in second half of next year - Goldman Sachs forecast described by Dan Struven Podcast recording date: August 4th and 5th, 2021 - End-of-episode disclosure

Pivotal Quotes: "The thing about Delta is it's more transmissible. So it basically has the ability to spread much more rapidly." — Terrence Flynn: Explaining why Delta became the predominant global strain "The vaccine efficacy against severe disease and hospitalization is still around 90%, even with the Delta variant." — Terrence Flynn: Summarizing the strongest protection from vaccination "We have lowered our U.S. growth forecasts moderately." — Dan Struven: Describing the macroeconomic impact of Delta on the U.S. outlook

Implications: Delta slows reopening unevenly: vaccines remain highly effective against severe outcomes, but rising cases can still depress consumer activity and growth. The biggest future risks are new variants, slower booster adoption, and lingering supply/labor bottlenecks.